PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19248197-6 2009 COX-1 and -2 mRNA levels were significantly increased in the EA group as compared to the control and ASA groups, and NO levels were also significantly increased in the EA group as compared to the ASA group. Aspirin 101-104 cytochrome c oxidase I, mitochondrial Rattus norvegicus 0-12 27161407-16 2016 DHI strengthened the inhibition activity of ASA on both COX-1 and COX-2, which showed that DHI alleviated ASA induced gastric mucosal damage but not antagonized anti-COX effect of ASA. Aspirin 44-47 cytochrome c oxidase I, mitochondrial Rattus norvegicus 56-61 26612417-5 2016 The present study investigated the effect of a common COX1/2 inhibitor (Aspirin) on macrophage phenotype and tissue remodeling in a rodent model of ECM scaffold treated skeletal muscle injury. Aspirin 72-79 cytochrome c oxidase I, mitochondrial Rattus norvegicus 54-60 26612417-13 2016 The COX1/2 inhibitor, Aspirin, was found to mitigate the ECM scaffold-mediated constructive remodeling response both in an in vitro co-culture system and an in vivo rat model of skeletal muscle injury. Aspirin 22-29 cytochrome c oxidase I, mitochondrial Rattus norvegicus 4-10 29439623-9 2018 The increased messenger RNA and protein levels of Cox1 and Cox2 induced by T0070907 were markedly reduced by aspirin treatment. Aspirin 109-116 cytochrome c oxidase I, mitochondrial Rattus norvegicus 50-54 17876871-10 2007 CONCLUSION: These results suggest that the effect of ULDA on platelet activity in portal hypertensive rats, could act through a COX 2 pathway more than the COX 1, predominant for aspirin at higher doses. Aspirin 179-186 cytochrome c oxidase I, mitochondrial Rattus norvegicus 156-161 12852480-5 2003 Hence, the developmental toxicity seen in rats after exposure to aspirin may be due to the irreversible inhibition of COX-1 and/or COX-2. Aspirin 65-72 cytochrome c oxidase I, mitochondrial Rattus norvegicus 118-123 17325651-8 2007 CONCLUSIONS AND IMPLICATIONS: Aspirin"s gastric toxicity in combination with a coxib can be dissociated from its ability to inhibit COX-1 and appears to be dependent, in part, on its ability to attenuate the stomach"s surface hydrophobic barrier. Aspirin 30-37 cytochrome c oxidase I, mitochondrial Rattus norvegicus 132-137 14592556-4 2003 Pretreatment with COX-1 and COX-3 inhibitors (aspirin at a low dose of 1 mg kg(-1), SC 560 and acetaminophen, 0.3-3 mg kg(-1)) slightly augmented thrombolysis by ACE-I, while COX-2 inhibitors (nimesulide and coxibs at doses <1 mg kg(-1) and aspirin at a high dose of 50 mg kg(-1)) or a kinin B2 receptor antagonist (icatibant) abolished it. Aspirin 46-53 cytochrome c oxidase I, mitochondrial Rattus norvegicus 18-23 14592556-4 2003 Pretreatment with COX-1 and COX-3 inhibitors (aspirin at a low dose of 1 mg kg(-1), SC 560 and acetaminophen, 0.3-3 mg kg(-1)) slightly augmented thrombolysis by ACE-I, while COX-2 inhibitors (nimesulide and coxibs at doses <1 mg kg(-1) and aspirin at a high dose of 50 mg kg(-1)) or a kinin B2 receptor antagonist (icatibant) abolished it. Aspirin 244-251 cytochrome c oxidase I, mitochondrial Rattus norvegicus 18-23 12852484-10 2003 Correlation of COX-1 and CA-4 expression with ASA sensitivity suggested that embryonic COX-1 and possibly CA4 are much more likely candidates for mediators of ASA developmental toxicity. Aspirin 46-49 cytochrome c oxidase I, mitochondrial Rattus norvegicus 15-20 12852480-20 2003 Such a finding is consistent with the concept that reversible inhibition of COX-1 and/or COX-2 by other NSAIDs would produce weaker developmental toxicity signals than aspirin. Aspirin 168-175 cytochrome c oxidase I, mitochondrial Rattus norvegicus 76-81 12852484-10 2003 Correlation of COX-1 and CA-4 expression with ASA sensitivity suggested that embryonic COX-1 and possibly CA4 are much more likely candidates for mediators of ASA developmental toxicity. Aspirin 159-162 cytochrome c oxidase I, mitochondrial Rattus norvegicus 87-92 8554334-2 1996 Clofibrate, perfluorooctanoic acid, and acetylsalicylic acid all increased the mRNA levels for the mitochondrial-encoded respiratory-chain components cytochrome c oxidase subunit I and NADH dehydrogenase subunit I. Mitochondrial 16S rRNA was also induced by clofibrate. Aspirin 40-60 cytochrome c oxidase I, mitochondrial Rattus norvegicus 150-203 11665868-11 2001 In vivo and in vitro studies suggest that NO-aspirin (acetylsalicylic acid) exerts more potent antithrombotic action than aspirin, probably by coupling the ability to inhibit COX-1 with the anti-adhesive effect of NO. Aspirin 45-52 cytochrome c oxidase I, mitochondrial Rattus norvegicus 175-180 11665868-11 2001 In vivo and in vitro studies suggest that NO-aspirin (acetylsalicylic acid) exerts more potent antithrombotic action than aspirin, probably by coupling the ability to inhibit COX-1 with the anti-adhesive effect of NO. Aspirin 54-74 cytochrome c oxidase I, mitochondrial Rattus norvegicus 175-180 11665868-11 2001 In vivo and in vitro studies suggest that NO-aspirin (acetylsalicylic acid) exerts more potent antithrombotic action than aspirin, probably by coupling the ability to inhibit COX-1 with the anti-adhesive effect of NO. Aspirin 122-129 cytochrome c oxidase I, mitochondrial Rattus norvegicus 175-180 9726391-0 1998 Activation of genes for spasmolytic peptide, transforming growth factor alpha and for cyclooxygenase (COX)-1 and COX-2 during gastric adaptation to aspirin damage in rats. Aspirin 148-155 cytochrome c oxidase I, mitochondrial Rattus norvegicus 86-108 9726391-13 1998 COX-1 expression was detected in vehicle-control gastric mucosa and after single exposure to ASA or after six consecutive ASA insults, while COX-2 mRNA was not detected in vehicle-control gastric mucosa, but appeared after single ASA insult and was sustained after subsequent ASA doses. Aspirin 93-96 cytochrome c oxidase I, mitochondrial Rattus norvegicus 0-5 9726391-13 1998 COX-1 expression was detected in vehicle-control gastric mucosa and after single exposure to ASA or after six consecutive ASA insults, while COX-2 mRNA was not detected in vehicle-control gastric mucosa, but appeared after single ASA insult and was sustained after subsequent ASA doses. Aspirin 122-125 cytochrome c oxidase I, mitochondrial Rattus norvegicus 0-5 9726391-13 1998 COX-1 expression was detected in vehicle-control gastric mucosa and after single exposure to ASA or after six consecutive ASA insults, while COX-2 mRNA was not detected in vehicle-control gastric mucosa, but appeared after single ASA insult and was sustained after subsequent ASA doses. Aspirin 122-125 cytochrome c oxidase I, mitochondrial Rattus norvegicus 0-5 9726391-13 1998 COX-1 expression was detected in vehicle-control gastric mucosa and after single exposure to ASA or after six consecutive ASA insults, while COX-2 mRNA was not detected in vehicle-control gastric mucosa, but appeared after single ASA insult and was sustained after subsequent ASA doses. Aspirin 122-125 cytochrome c oxidase I, mitochondrial Rattus norvegicus 0-5 9622204-3 1998 Experiments with acetylsalicylic acid showed that 80% of PGE2 production after 1 h of treatment with LPS is accounted for by COX-1; this figure decreases to about 30% after a 24-h treatment. Aspirin 17-37 cytochrome c oxidase I, mitochondrial Rattus norvegicus 125-130 9627095-10 1998 Aspirin, but not NCX-4016, markedly suppressed systemic COX-1 and COX-2 activity, and colonic prostaglandin synthesis. Aspirin 0-7 cytochrome c oxidase I, mitochondrial Rattus norvegicus 56-61 9152412-7 1997 After the macrophages were treated with aspirin to inactivate existing COX-1 and COX-2, however, treatment with 12-0-tetradecanoylphorbol 13-acetate increased PGE2 production. Aspirin 40-47 cytochrome c oxidase I, mitochondrial Rattus norvegicus 71-76